G Medical Holdings Ltd (GMVD)
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against G Medical Holdings Ltd (“G Medical” or the “Company”) (NASDAQ: GMVD). Investors who purchased G Medical securities are encouraged to obtain additional information and assist in the investigation.
The investigation concerns whether G Medical violated federal securities laws.
On or around June 24, 2021, G Medical conducted its initial public offering (“IPO”), issuing 3 million shares priced at $5.00. Then, on November 22, 2022, G Medical disclosed receipt of “a written notice (the ‘Notice’) from Nasdaq Stock Market LLC, indicating that the Company is no longer in compliance with the minimum shareholders’ equity requirement for continued listing on the Nasdaq Capital Market.” G Medical further stated that “the Company has 45 calendar days, or until January 6, 2023, to submit a plan to regain compliance.” Since its IPO, G Medical’s stock price has fallen more than 31%, damaging investors.
If you are aware of any facts relating to this investigation or purchased G Medical securities, you can assist in this investigation. You can also contact Peretz Bronstein or his Investor Relations Analyst, Yael Nathanson of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484.
Bronstein, Gewirtz & Grossman, LLC represents investors in securities fraud class actions and shareholder derivative suits. The firm has recovered hundreds of millions of dollars for investors nationwide. Attorney advertising. Prior results do not guarantee similar outcomes.